Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002
Induction of M. tuberculosis (MTB) drug resistance (DR) mutations in HIV-infected hosts and pathways of further spread of the evolutionary successful drug-resistant MTB clonal lines Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Considerations upon the drug resistance spectrum of Mycobacterium tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 313s Year: 2001
The problem of one drug resistance in tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 858s Year: 2006
Mycobacterium abscessus activates cross-resistance following antibiotic exposure Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis Source: Eur Respir J, 50 (6) 1701354; 10.1183/13993003.01354-2017 Year: 2017
Drug resistance of Mycobacterium tuberculosis isolated from tuberculosis inflammatory foci Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005
Dependending on drug resistance character of bacteriostatic blood activity at time polychemotherapy against of M. tuberculosis strains isolated from patients Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002
Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Change of M. tuberculosis drug susceptibility spectrum during chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 11s Year: 2006
Method of treatment of destructive tuberculosis of single lung with extensively drug resistant mycobacteria tuberculosis Source: Annual Congress 2011 - Extrapulmonary tuberculosis and surgical interventions Year: 2011
In vitro and vivo study of isoxyl, a mycolic acid inhibitor for intermittent chemotherapy of multi drug resistant (MDR) strains of mycobacterium tuberculosis (M.tb)Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections Source: Eur Respir J, 49 (5) 1700083; 10.1183/13993003.00083-2017 Year: 2017
Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001
Treatment‘s side effects in MDR tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 454s Year: 2005
Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis : contribution of murine studies Source: Eur Respir J, 57 (4) 2004315; 10.1183/13993003.04315-2020 Year: 2021
Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017
The Glutoxim influence on minimum inhibitory concentration of isoniazid-resistant strains of Mycobacterium tuberculosis Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019
Mycobacterium tuberculosis drug resistance surveillance in BelarusSource: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005
Determination of drug susceptibility of Mycobacterium tuberculosis through mycolic acid analysis with HPLC technique - comparison to the conventional methods Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005